Genital condylomata in a patient receiving infliximab for Crohn's disease.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15192172.
- Also identified by PMC identifier 1743010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Infliximab is a monoclonal antibody against tumour necrosis factor-alpha. Recent studies have shown that it is effective in treating patients with refractory Crohn's disease and in those with Crohn's fistulae. Though this drug is found to be safe in clinical trials, sporadic reports of serious complications have been recorded in the literature. The case of a patient who developed profuse genital warts after infliximab treatment is reported. The literature is reviewed and information is presented on side effects and complications as a result of infliximab therapy.
Medical subject headings
- Antibodies, Monoclonal
- Condylomata Acuminata
- Crohn Disease
- Gastrointestinal Agents
- Penile Diseases